Archives of Pharmacal Research

, Volume 28, Issue 6, pp 730–735 | Cite as

Polymorphism of doxazosin mesylate

  • Young-Taek Sohn
  • Yoon-Hee Lee
Articles Drug Efficacy


Nine polymorphic modifications of doxazosin mesylate have been obtained by recrystallization in organic solvents under variable conditions. Different polymorphs of doxazosin mesylate were characterized by powder X-ray crystallography diffractometry (PXRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TG). Transformation of Form 1 and Form 2 was not occurred in three relative humidities (0%, 51%, and 99%) at 20±0.5 for 30 days.

Key words

Doxazosin mesylate Polymorphism PXRD DSC TG Transformation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Borka, L., Reviews on crystal polymorphism of substances in the European Pharmacopoeia.Pharm Acta Helv., 66, 16–22 (1991).PubMedGoogle Scholar
  2. Giron, D., Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates.Thermochim. Acta, 248, 1–59 (1995).CrossRefGoogle Scholar
  3. Grcman, M., Vrecer, F., and Meden, A., Some physico-chemical properties of Doxazosin mesylate polymorphic forms and its amorphous state.J. Them. Anal. Cal., 68, 373–387 (2002).CrossRefGoogle Scholar
  4. Gridhar, T., Reddy, R. B., and Ramesh, C., Methods for the preparation of polymorphs of doxazosin mesylate.US 6, 399, 775B1 (2002).Google Scholar
  5. Gruenenberg, A., Polymorphie und thermische Analyse pharmazeutischer WirkstoffePharmazie in unserer Zeit, 26, 224–231 (1997).CrossRefGoogle Scholar
  6. Haleblian, J. and McCrowne, W., Pharmaceutical applications of polymorphism.J. Pharm. Sci., 58, 911–929 (1969).PubMedCrossRefGoogle Scholar
  7. Haleblian, J., Characterization, of habits and crystalline modification of solids and their pharmaceutical applications.J. Pharm. Sci., 65, 1269–1288 (1975).CrossRefGoogle Scholar
  8. Kuhnert-Brandstaetter, M., Polymorphie von Arzneitoffen und ihre Bedeutung in der pharmazeutischen Technologie.Informationsdienst A.P.V., 19, 73–90 (1973).Google Scholar
  9. Sohn, Y. T., Effect of polymorphism on bioavailability of amoxicillin.Yakhak Hoeji, 39, 438–443 (1995).Google Scholar
  10. Sohn, Y. T. and Kim, S. Y., Effect of crystal form onin vivo topical anti-inflammatory activity of corticosteroids.Arch. Pharm Res., 25, 556–559 (2002).PubMedCrossRefGoogle Scholar
  11. Sun, C. and Grant, D. J. W., Influence of crystal structure on the tableting properties of sulfamerazine polymorphs.Pharm. Res., 18, 274–280 (2001).PubMedCrossRefGoogle Scholar
  12. Yoshinari, T., Forbes, R. T., York, P., and Kawashima, Y., The improved compaction properties of mannitol after a moisture-induced polymorphic transition.Int. J. Pharm., 258, 121–131 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2005

Authors and Affiliations

  1. 1.College of PharmacyDuksung Women's UniversitySeoulKorea

Personalised recommendations